Molecular building blocks are mainly used in drug discovery and the synthesis of target compounds in organic methodology, and are important fragments that make up drug molecules
.
Data shows that 30% of global pharmaceutical R&D spending is spent on the purchase and outsourcing
of drug molecular building blocks.
At present, domestic enterprises have also entered one after another, and the industry said that there is great potential
for the overall development of the molecular block industry.
At present, the main products in the international drug molecular building block market such as the United States and Europe are mainly Sigma-Aldrich, Combi-Blocks, Enamine and TCI, while domestic drug molecular building block enterprises represented by PharmaBlock Technology, Haoyuan Pharmaceutical, Aladdin and Bide Pharma are constantly entering the market, with a strong import substitution effect
.
Taking Bede Pharma as an example, the company is a domestic molecular building block company below the kilogram level, which gathers at the front end of new drug research and development, mainly serving the key links
of new drug research and development, such as drug target discovery, emerging compound synthesis and screening, lead compound discovery synthesis and optimization, and drug candidate discovery.
It is reported that Bede Pharmaceutical has been engaged in the R&D and design of drug molecular building blocks and scientific reagents for many years, and has a mature and powerful R & D and design technology system for drug molecular building blocks, which can provide customers with novel structure and diverse functions of drug molecular building blocks and scientific reagents, so as to meet the characteristics of downstream customers' high-tech, multi-category, micro-dose and multi-frequency products, and occupy an important position
in the pharmaceutical molecular building block industry chain 。 Among them, in recent years, with the domestic and foreign demand for boron-containing and fluorine-containing drug molecular building blocks increasing year by year, Bede Pharma is focusing on its independent research and development, grading products according to quality, and constantly improving the reserve, which is expected to become a new focus
in the future.
PharmaBlock uses its novel molecular building blocks and related compound library screening technology to help drug discovery; And build an integrated CMC platform to provide efficient and high-quality process development and production services
for intermediates, APIs and pharmaceutical preparations for innovative drug R&D and commercialization projects.
The data shows that in 2021, PharmaBlock's operating income constitutes 100.
0%
of the research and development of Chinese medicine molecular building blocks.
It is reported that most of PharmaBlock's drug molecular building blocks are independently developed and are not subject to intellectual property confidentiality clauses, and can be supplied to multiple customers
at the same time.
The front-end business of Haoyuan Pharmaceutical is mainly divided into two sub-categories
: molecular building blocks and tool compounds.
In the first three quarters of 2022, the company's molecular block revenue was 178 million yuan, a year-on-year increase of 75.
60%.
According to public information, as of the end of September 2022, the cumulative reserve molecular building blocks of Haoyuan Pharmaceutical reached about 57,000, an increase of about 15,000 compared
with the number at the end of 2021.
According to the industry, Haoyuan Pharmaceutical can better understand the trend and demand of domestic research and development, and while continuously improving the number of molecular building block product types, Haoyuan Pharmaceutical is also strengthening differential competition, and creating a more differentiated product library
with Haoyuan characteristics in terms of category selection.
It is understood that molecular building blocks are mainly used in drug development and the synthesis of target compounds in organic methodology, and are important fragments that make up drug molecules
.
Starting from the molecular building blocks, the target small molecule can be obtained by chemical synthesis, which can save 2~10 times or even more time, the researchers conduct in vivo and in vivo activity tests on the target small molecule, and further optimize the structure of the small molecule according to the experimental results, so repeatedly, and finally screen out the lead compound or preclinical candidate compound
.
At present, many pharmaceutical companies at home and abroad will spend millions or more to establish their own internal molecular building block resource library, providing a large number of reliable molecular building block product bases
for the synthesis of new molecules.
According to the industry, the molecular building block industry is vast, and 30% of the global pharmaceutical R&D expenditure is used for the purchase and outsourcing of drug molecular building blocks, and it is estimated that the global molecular building block market space will be about 25.
3 billion US dollars in 2023 and will reach 54.
6 billion US dollars by 2026.
The domestic molecular block market started late, and it is still in the stage
of continuous development of product categories.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
